Clinical Trial Update: Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study evaluating topical FOV2304 for center-involving clinically significant macular edema associated with diabetic retinopathy has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• FOV2304 (FOV2304)

Snippet

Sponsor: Fovea Pharmaceuticals SA | Conditions: Diabetic Macular Edema | Phase 2 | Status: COMPLETED